COPPER-ATOM IDENTIFICATION IN THE DIFFERENT ACTIVE AND INACTIVE FORMS OF RECOMBINANT FACTOR-VIII-DELTA-II AND PLASMA-DERIVED FACTOR-VIII

被引：0
|
作者：
BIHOREAU, N
RAMON, C
PIN, S
FONTAINEAUPART, MP
机构：
[1] LAB FRANCAIS FRACTIONNEMENT & BIOTECHNOL,LES ULIS,FRANCE
[2] UNIV PARIS 11,PHOTOPHYS MOLEC LAB,F-91405 ORSAY,FRANCE
[3] UNIV DENIS DIDEROT,BIOL PHYSICOCHIM LAB,PARIS,FRANCE
来源：
THROMBOSIS AND HAEMOSTASIS | 1995年 / 73卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1215 / 1215
页数：1
相关论文
共 50 条
  • [41] Comparative Glycosylation Mapping of Recombinant and Plasma-Derived Human Factor VIII Reveals Key Biological Differences
    Qu, Jingyao
    Ma, Cheng
    Miao, Carol H.
    Wang, Peng George
    Xiao, Weidong
    BLOOD, 2017, 130
  • [42] Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII
    Scharrer, I
    Ehrlich, HJ
    HAEMOPHILIA, 2001, 7 (04) : 346 - 348
  • [43] CHARACTERIZATION OF DELETED RECOMBINANT FACTOR-VIII (FACTOR-VII-DELTA-II) PRODUCED BY CHO CELLS IN A SERUM FREE MEDIUM
    BIHOREAU, N
    SAUGER, A
    PAOLANTONACCI, P
    MIGNOT, G
    KRISHNAN, S
    ROMELEMONNE, JL
    THROMBOSIS AND HAEMOSTASIS, 1991, 65 (06) : 945 - 945
  • [44] INCIDENCE OF FACTOR-VIII INHIBITOR DEVELOPMENT IN HEMOPHILIA-A PATIENTS TREATED WITH LESS PURE PLASMA-DERIVED CONCENTRATES
    DEBIASI, R
    ROCINO, A
    PAPA, ML
    SALERNO, E
    MASTRULLO, L
    DEBLASI, D
    THROMBOSIS AND HAEMOSTASIS, 1994, 71 (05) : 544 - 547
  • [45] Lower inhibitor risk of plasma-derived factor VIII concentrates versus recombinant factor VIII concentrates in patients with severe haemophilia A : result from SIPPET study and comments
    Biron-Andreani, Christine
    Diaz, Isabelle
    Navarro, Robert
    Schved, Jean-Francois
    HEMATOLOGIE, 2019, 25 (02): : 93 - 99
  • [46] Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro
    Astermark, J
    Voorberg, J
    Lenk, H
    Dimichele, D
    Shapiro, A
    Tjönnfjord, G
    Berntorp, E
    HAEMOPHILIA, 2003, 9 (05) : 567 - 572
  • [47] B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate: a randomized, three-way crossover study
    Kessler, CM
    Gill, JC
    White, GC
    Shapiro, A
    Arkin, S
    Roth, DA
    Meng, X
    Lusher, JM
    HAEMOPHILIA, 2005, 11 (02) : 84 - 91
  • [48] PRECLINICAL STUDIES OF A DELETED RECOMBINANT FACTOR-VIII, FVIII-DELTA-II .1. MANUFACTURING PROCESS AND EFFICACY
    PAOLANTONACCI, P
    DHAINAUT, F
    BIHOREAU, N
    LIROCHON, J
    GERMAIN, C
    SAUGER, A
    GUERIN, P
    THROMBOSIS AND HAEMOSTASIS, 1993, 69 (06) : 855 - 855
  • [49] Interferon-gamma secretion defects in haemophilia A patients receiving highly purified plasma-derived or recombinant factor VIII
    NewtonNash, DK
    Tollerud, D
    Guevarra, L
    Gill, JC
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 95 (03) : 554 - 560
  • [50] The role of VWF in FVIII/VWF concentrates: biochemical characterization of three different plasma-derived factor VIII products
    Cristofaro, Raimondode
    Lancellotti, Stefano
    Filippis, Vincenzode
    Acquasaliente, Laura
    Valsecchi, Carla
    Garagiola, Sabella
    Peyvandi, Flora
    HAEMOPHILIA, 2014, 20 : 26 - 26
12345